Idrx company information, Employees & Contact Information

GSK enters agreement to acquire IDRx, Inc. GSK

IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 Oncodaily

GSK Targets Rare Cancer With $1B+ Acquisition of IDRx BioSpace

GSK to buy cancer-focused IDRx in $1 billion deal statnews.com

JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care Fierce Biotech

GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug Endpoints News

GSK to buy US cancer drug firm IDRx for up to $1.15bn The Guardian

GSK Nears $1 Billion Deal for Biotech Company IDRx Bloomberg

GSK completes acquisition of IDRx, Inc. GSK

GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition PMLiVE

[Updated] ID Digest: Digital bank Yup, crypto platform IDRX raise funding DealStreetAsia

The gist of GSK's move is to follow Ono | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

JP Morgan 2025: GSK acquires IDRx in $1.15bn deal Pharmaceutical Technology

GSK to buy US biotech firm IDRx for up to $1.15 billion Reuters

IDRx Appoints Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO citybiz

GSK has announced agreement to acquire the U.S. biotech firm IDRx for up to $1.15 billion Oncodaily

CTOS 2023 – IDRx looks to outdo Deciphera | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST) Business Wire

ASCO 2024 – IDRx shoots for an early-line gist | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GSK to Buy US Cancer Biotech IDRx for Up to $1.15 Billion Bloomberg

Will rumoured GSK purchase of IDRx be first JP Morgan 2025 deal? FirstWord Pharma

GSK to buy IDRx for $1B upfront, expanding gastrointestinal cancer pipeline FirstWord Pharma

IDRx raises $120m to fund gastric tumour trials for lead TKI therapy Pharmaceutical Technology

IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies Business Wire

IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST Business Wire

British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal Fortune

GSK confirms plan to buy cancer firm IDRx for $1bn pharmaphorum

Investing in IDRx Andreessen Horowitz

Rock Springs Capital-backed IDRx Closes on $120 Million Series B citybiz

IDRx launches with $122M to treat cancer with precision combination therapies Labiotech.eu

C-Suite Shuffle: Sumitomo, Kineta, IDRx and More BioSpace

GSK Agrees to Acquire IDRx Contract Pharma

IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations BioPharma Dive

IDRx launches with $122M to develop combo therapy that addresses precision medicine 'whack-a-mole' Fierce Biotech

UK: GSK to acquire IDRx for up to US$1.15bn Investors in Healthcare

With $122M, Startup IDRx Intends to Stop Cancer Mutations in their Tracks BioSpace

GSK boosts cancer drug pipeline with $1B acquisition of IDRx ET Pharma

GSK to acquire biotech company IDRx for up to $1.15 billion domain-b.com

Startup IDRx raises $122m to focus on combination drug treatments The Boston Globe

GSK to buy US cancer biotech IDRx for up to US$1.15 billion The Business Times